NanoString Provides Updates on nCounter Elements Launch, Prosigna Rollout, Gen3 System Development | GenomeWeb

NEW YORK (GenomeWeb) – NanoString Technologies continues to benefit from sales to clinical laboratories. The Seattle-based company saw its revenues grow 54 percent in the first quarter, driven by a 110 percent increase in instrument placements, 40 percent of which were of its nCounter Dx system for dual research and clinical diagnostic use.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.